<DOC>
	<DOCNO>NCT00950417</DOCNO>
	<brief_summary>Nimotuzumab ( hR3 ) IgG1 humanize monoclonal antibody recognize epitope locate extra cellular domain human epidermal growth factor receptor ( EGFR ) . Clinical efficacy show adult head neck cancer . The phase I study assessed safety , efficacy combination Nimotuzumab administer concomitantly chemo-radiotherapy patient locally advanced esophageal cancer tumour .</brief_summary>
	<brief_title>Nimotuzumab Combination With Chemoradiation Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Informed consent form sign perform study 's specific procedure . ECOG performance status 02 . Age &gt; 18 &lt; 75 . Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) criterion , great equal 1 cm ( long diameter ) spiral compute tomography ( CT ) scan MRI great equal 2 cm ordinary radiographic technique . Histologically confirm diagnosis locally advanced esophageal . Life expectancy 3 month . Use effective contraceptive method patient sex risk conception and/or pregnancy . No serious blood produce , abnormal function heart , lung , liver , kidney immunodeficiency Neutrophils ≥3×109/L , platelet count≥100×109/L haemoglobin≥9g/dL , Creatinine ≤ 1.5 x NUL Previous radiotherapy chemotherapy Pregnant breastfeed woman Drug abuse , unhealthy drug/alcohol addiction , virus ( HIV ) infection Evidence distant metastasis Participation clinical trial Patients aphthosis , complete obstruction , fistula deep peptic ulcer esophagus , haematemesis Uncontrolled psychiatric disease seizure Patients fit clinical trial judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>nimotuzumab esophageal chemo-radiotherapy</keyword>
</DOC>